lonapegsomatropin lonapegsomatropin lonapegsomatropin, sold under the brand name skytrofa, is a human growth hormone used for the treatment of growth hormone deficiency. lonapegsomatropin is a prodrug of somatropin. lonapegsomatropinclinical datatrade namesskytrofaother nameslonapegsomatropin-tcgd; rhgh-peg; acp-011; τransconpeg hgh; who-10598license data us dailymed: lonapegsomatropin routes ofadministrationsubcutaneous injectiondrug classgrowth hormone receptor agonistatc codeh01ac09 (who) legal statuslegal status us: ℞-only eu: rx-only identifierscas number1934255-39-6pubchem sid381128171drugbankdb16220uniiop35x9610ykeggd11486chemblchembl4298185chemical and physical dataformulac1051h1627n269o317s94n lonapegsomatropin was approved for medical use in the united states in august 2021, and in the european union in january 2022. medical uses lonapegsomatropin is a growth hormone therapy indicated to treat growth hormone deficiency. history the us food and drug administration granted the application for lonapegsomatropin orphan drug designation.